AbbVie (ABBV) Stock Forecast, Price & News

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 8 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ABBV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares.
View ABBV analyst ratings or view top-rated stocks.

14 brokerages have issued 1 year price targets for AbbVie's stock. Their ABBV share price forecasts range from $140.00 to $195.00. On average, they anticipate the company's stock price to reach $163.40 in the next year. This suggests a possible upside of 18.3% from the stock's current price.
View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts.

AbbVie's stock was trading at $161.61 on January 1st, 2023. Since then, ABBV shares have decreased by 14.5% and is now trading at $138.16.
View the best growth stocks for 2023 here.

AbbVie saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 11,970,000 shares, a decrease of 23.5% from the April 30th total of 15,650,000 shares. Based on an average daily volume of 5,780,000 shares, the short-interest ratio is presently 2.1 days. Approximately 0.7% of the company's shares are sold short.
View AbbVie's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our ABBV earnings forecast.

AbbVie Inc. (NYSE:ABBV) released its quarterly earnings data on Thursday, April, 27th. The company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.44 by $0.02. The firm had revenue of $12.23 billion for the quarter, compared to analysts' expectations of $12.23 billion. AbbVie had a trailing twelve-month return on equity of 153.92% and a net margin of 13.37%. AbbVie's revenue for the quarter was down 9.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.16 earnings per share.
Read the conference call transcript.

AbbVie announced a quarterly dividend on Thursday, February 16th. Shareholders of record on Friday, April 14th will be paid a dividend of $1.48 per share on Monday, May 15th. This represents a $5.92 annualized dividend and a yield of 4.28%. The ex-dividend date of this dividend is Thursday, April 13th.
Read our dividend analysis for ABBV.

ETFs with the largest weight of AbbVie (NYSE:ABBV) stock in their portfolio include First Trust Morningstar Dividend Leaders Index (FDL), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Horizon Kinetics Medical ETF (MEDX), iShares Core High Dividend ETF (HDV), Invesco Dynamic Pharmaceuticals ETF (PJP), Sound Equity Income ETF (SDEI), iShares U.S. Healthcare ETF (IYH) and Kelly CRISPR & Gene Editing Technology ETF (XDNA).

AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 4.34%. ABBV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 139.95%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 53.62% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

AbbVie updated its second quarter 2023 earnings guidance on Friday, April, 28th. The company provided EPS guidance of $2.90-$3.00 for the period, compared to the consensus EPS estimate of $2.85. The company issued revenue guidance of $13.50 billion-$13.50 billion, compared to the consensus revenue estimate of $13.36 billion.

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Rogers Communications (RCI) and Open Text (OTEX).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.86%), State Street Corp (4.37%), Geode Capital Management LLC (1.93%), Charles Schwab Investment Management Inc. (1.22%), Bank of New York Mellon Corp (1.14%) and Price T Rowe Associates Inc. MD (1.00%). Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents and Timothy J Richmond.
View institutional ownership trends.

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABBV stock can currently be purchased for approximately $138.16.

AbbVie (NYSE:ABBV) has a market capitalization of $243.75 billion and generates $58.05 billion in revenue each year. The company earns $11.84 billion in net income (profit) each year or $4.23 on an earnings per share basis.

The company employs 50,000 workers across the globe.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The official website for the company is www.abbvie.com. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.